ORPHA:90280
Chilblain lupus
Query health: suspect — Only one of 2 strategies returned hits (phrase).
Publications
845
Trials
0
Interventional, condition-specific
Researchers
1,054
Distinct authors in sample
Gene link
SAMHD1
Disputed
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A rare, chronic cutaneous lupus erythematosus disease characterized by red or violaceous, initially pruritic (evolving to painful) papules and plaques located on acral areas (especially dorsal aspects of fingers and toes, while the nose and ear involvement is uncommon), exacerbated by cold and damp conditions, with fissuring and ulceration occasionally observed. Coexistence of discoid lupus erythematosus lesions elsewhere on the body and occasional progression to systemic lupus erythematosus may be associated. Histological examination and direct immunofluorescence studies reveal nonspecific inflammatory lupus erythematosus changes while results of cryoglobulin and cold agglutinin studies are negative.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0019557
- UMLS:C4551515
Additional Mondo synonyms (2)
CHLE · Hutchinson lupus
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
No matched interventional trial; the gene is known and literature exists — preclinical or natural-history work may still be the practical next step.
- Gene identifiedPartial
Disputed — SAMHD1
- LiteraturePresent
845 matched papers (582 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Uncertain — earlier gene claims are disputed or refuted.
GenCC classification: Disputed.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
845
845 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
845 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
582 in the last 10 years · low confidence
Phrase hits: 845 · MeSH hits: 0
Who's working on it?
1,054
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Günther C11 papers · 2025
Department of Dermatology, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany.
Papers in Europe PMC - 02Lee-Kirsch MA7 papers · 2025
Department of Pediatrics, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany.
Papers in Europe PMC - 03Wolf C7 papers · 2025
Department of Pediatrics, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany.
Papers in Europe PMC - 04Klein B5 papers · 2025
Department of Dermatology, Venereology and Allergology, University Medicine Leipzig, Leipzig, Germany.
Papers in Europe PMC - 05Zimmermann N5 papers · 2022
Department of Dermatology, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany.
Papers in Europe PMC - 06Beissert S4 papers · 2023
Department of Dermatology, Medical Faculty Carl Gustav Carus, TU Dresden, 01307 Dresden, Germany.
Papers in Europe PMC - 07Crow YJ4 papers · 2026
Paris Descartes University, Sorbonne-Paris-Cité, Paris, France.
Papers in Europe PMC - 08Liu Y4 papers · 2023
Department of Medical Genetics and National Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100005, China. ypliu@ibms.pumc.edu.cn.
Papers in Europe PMC - 09Xiao J4 papers · 2026
Department of Dermatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Papers in Europe PMC - 10Frémond ML3 papers · 2026
Department of Paediatric Haematology-Immunology and Rheumatology, Hôpital Necker-Enfants Malades, AP-HP, Paris, France.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
low confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Chilblain lupus" OR "Hutchinson lupus"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Chilblain lupus" OR "Hutchinson lupus" OR "SAMHD1"
Recall-expansion terms: SAMHD1
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: suspect — strategies attempted: phrase, recall-expansion; with hits: phrase
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: CHLE
Confidence reasoning
- Preferred label is multi-word and distinctive
- 1 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
- Publication count (845) is implausibly high for prevalence class "<1 / 1 000 000" — treat as possible over-matching, not a measure of research intensity
Ingested 2026-07-27T03:41:59.013Z